2013
DOI: 10.1016/j.ijpharm.2013.05.006
|View full text |Cite
|
Sign up to set email alerts
|

Novel alternatives to reduce powder retention in the dry powder inhaler during aerosolization

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
19
0

Year Published

2013
2013
2020
2020

Publication Types

Select...
7
1

Relationship

2
6

Authors

Journals

citations
Cited by 23 publications
(19 citation statements)
references
References 52 publications
0
19
0
Order By: Relevance
“…The drug retention could be minimised by coating the drug capsule and delivery device with pharmaceutically acceptable force-control agents (30). Irrespective of the dose strength, the residual amount in the capsule after two separate inhalations (RA/Cap), residual amount in the device (RA/Dev) and the total residual amount in capsule and device (TRA/RA(Cap) + RA(Dev)) were decreased with increasing of MIF and Vin (Tables II and III).…”
Section: Resultsmentioning
confidence: 99%
“…The drug retention could be minimised by coating the drug capsule and delivery device with pharmaceutically acceptable force-control agents (30). Irrespective of the dose strength, the residual amount in the capsule after two separate inhalations (RA/Cap), residual amount in the device (RA/Dev) and the total residual amount in capsule and device (TRA/RA(Cap) + RA(Dev)) were decreased with increasing of MIF and Vin (Tables II and III).…”
Section: Resultsmentioning
confidence: 99%
“…(2014) 12 (6) to be a concern that can potentially lead to underdosing. The FPF of a DPI is anywhere between 20 and 30% [74], compared to device retention up to 15 --60% in another study [75].…”
Section: Dry Powder Inhalers In Copd Lung Inflammation and Pulmonarymentioning
confidence: 87%
“…Reducing device retention and enhancing the emitted dose can be achieved when using anti-adherent or anti-friction excipients (e.g., magnesium stearate, leucine, lecithin), which reduces friction drag and improves drug dispersion [75]. These agents, also called as force-control agents, are added to the formulation in addition to coating the device surface and capsule [71,75].…”
Section: Dry Powder Inhalers In Copd Lung Inflammation and Pulmonarymentioning
confidence: 99%
See 1 more Smart Citation
“…The lower FPF might be due to the cohesiveness and hygroscopicity of the powder, which could in a way be inferred by the formulation's high capsule and device retention (i.e., 12.6 ± 2.8% and 29.0 ± 2.9%, respectively [ Fig. 5b]) 70 and sorption characteristics (Fig. 4a).…”
Section: In Vitro Aerosol Performancementioning
confidence: 99%